Merck and Genetronics Collaborate on DNA Delivery System

(Whitehouse Station, NJ, USA) and Genetronics Biomedical Corp. (San Diego, CA, USA), the MedPulser DNA delivery system of Genetronics will be developed and commercialized for use with certain of Merck's DNA vaccine programs. The agreement is an extension of an initial evaluation agreement established in 2003.

Under the terms of the agreement, Merck receives the right to use Genetronics' proprietary technology initially for two specific antigens, with an option to extend the agreement to include a limited number of additional target antigens. Genetronics will receive an upfront payment as well as milestone payments linked to the successful development of a product, with royalties payable on sales of a product utilizing the MedPulsar device and developed under the agreement.

In addition, Merck obtains a nonexclusive license to Genetronics' intellectual property. The companies will codevelop certain components of the electroporation system designed for administering DNA vaccines. Merck will be responsible for all development costs and clinical programs.

"Among the key obstacles to the commercialization of DNA vaccines are the limitations associated with viral and lipid delivery systems. Merck is at the forefront of DNA vaccine research and development, and appreciates the strategic value of developing an optimal delivery solution to realize the clinical and commercial benefits of DNA vaccines,” said Avtar Dhillon, M.D., president and CEO of Genetronics.



Related Links:
Merck
Genetronics